Metformin (500mg) + Voglibose (0.2mg)
Vozuca-M Activ Tablet SR is used in the treatment of type 2 diabetes.
1 Bottle of 60 Tablet
Image shown is a representation and may slightly vary from the actual product. Every effort is made to maintain accuracy of all information displayed.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Vozuca-M Activ Tablet SR is to be taken with food.
Vozuca-M Activ Tablet SR may cause stomach upset if taken on empty stomach.
Vozuca-M Activ Tablet SR is a combination of two antidiabetic medicines: Metformin and voglibose. Metformin lowers the production and absorption of sugar in your body and allows better use of existing insulin. Voglibose inhibits the intestinal enzymes that cause breakdown of complex sugars into simple sugars such as glucose. This prevents blood glucose from rising very high after meals.
Related Warnings
Taking Voglibose with alcohol reduce the blood sugar levels in diabetic patients.
Vozuca-M Activ Tablet SR is probably safe to use during pregnancy.
Animal studies have shown low or no adverse effect on the foetus, however, there are limited human studies. Please consult your doctor.
Vozuca-M Activ Tablet SR is probably safe to use during lactation. Limited human data suggests that the drug does not represent a significant risk to the baby.
Your ability to drive may be affected if your blood sugar is low or high. If this happens, do not drive.
Vozuca-M Activ Tablet SR should be used with caution in patients with kidney disease. Dose adjustment of Vozuca-M Activ Tablet SR may be needed. Please consult your doctor.
Use of Vozuca-M Activ Tablet SR is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Vozuca-M Activ Tablet SR should be used with caution in patients with liver disease. Dose adjustment of Vozuca-M Activ Tablet SR may be needed. Please consult your doctor.
Vozuca-M Activ Tablet SR is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.
